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bstract
Familial hypercholesterolaemia (FH) is characterised clinically by an increased level of circulating LDL cholesterol that leads to lipid
ccumulation in tendons and arteries, premature atherosclerosis and increased risk of coronary heart disease (CHD). Although Portugal
hould have about 20,000 cases, this disease is severely under-diagnosed in our country, this being the first presentation of Portuguese data
n FH. A total of 602 blood samples were collected from 184 index patients and 418 relatives from several centres throughout Portugal.
ifty-three different mutations were found in 83 index patients, 79 heterozygous and 4 with two defective LDLR alleles. Additionally, 4
utative alterations were found in 8 patients but were not considered mutations causing disease, mainly because they did not co-segregate with
ypercholesterolaemia in the families. Three unrelated patients were found to be heterozygous for the APOB3500 mutation and two unrelated
atients were found to be heterozygous for a novel mutation in PCSK9, predicted to cause a single amino acid substitution, D374H. Cascade
creening increased the number of FH patients identified genetically to 204. The newly identified FH patients are now receiving counselling
nd treatment based on the genetic diagnosis. The early identification of FH patients can increase their life expectancy and quality of life by
reventing the development of premature CHD if patients receive appropriate pharmacological treatment.
2007 Elsevier Ireland Ltd. All rights reserved.
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ominant disorder with a frequency of about 1/500 in most
uropean countries [1]. FH usually results from inherited
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efects in the low density lipoprotein receptor gene (LDLR)
ut mutations in the gene for apolipoprotein B (APOB) or,
ore recently described, mutations in the proprotein con-
ertase subtilisin/Kexin type 9 (PCSK9) gene also cause
he same phenotype. FH is clinically characterised by an
ncreased level of circulating LDL cholesterol that leads to
ipid accumulation in tendons (xanthomas) and arteries, pre-
ature atherosclerosis and increased risk of coronary heart
isease (CHD). Although Portugal should have about 20,000
ases, this disease is severely under-diagnosed in our country
here no prior clinical or genetic studies have been per-
ormed. Men and women with FH aged between 20 and 39
ears old have an 100-fold increased risk to develop pre-
ature CHD compared to the normal population [2]. It is
mportant to identify as early as possible individuals with
H to improve their prognosis by administration of appropri-
te therapeutic interventions and also to allow provision of
enetic counselling and to ensure access to specialised medi-
al services. The aim of this project was to set up a network of
ipid clinics and an analytical laboratory for the “Portuguese
H study” [3] and perform the molecular characterization of
atients with a clinical diagnosis of Familial hypercholes-
erolaemia (FH) to allow cascade screening of the relatives
f index patients. It was also expected that comparison of
he clinical and molecular characteristics of Portuguese FH
atients with FH patients from other countries may provide
ome insight about the underlying reason for the different
everity of the phenotypes presented by FH patients.
. Methods.1. Patient recruitment
A total of 602 blood samples were collected from 184
ndex patients and 418 relatives of 124 of these families.
p
w
G
e
ig. 1. Demographic distribution of Clinicians and index patients participating in
ollaborating with the Portuguese FH study. (B) Origin of 184 unrelated index patisis 196 (2008) 633–642
he 184 index patients, 51 children (aged 18-year old or
nder) and 133 adults, were referred to our institute by 21
linicians working in public hospitals, mainly in cardiology,
nternal medicine, paediatric and genetic services, through-
ut the country and islands (Fig. 1). A clinical questionnaire
dapted from the “Simon Broome Heart Research Study”
4] was completed by clinicians for each index patient and
nformed consent was signed by all index patients and rela-
ives. For children under 18 the declaration was signed by the
arents.
.2. Biochemical characterization
The biochemical parameters including total choles-
erol, HDL cholesterol, triglycerides, apolipoprotein AI,
polipoprotein B and lipoprotein (a), were determined for all
ubjects in an Hitachi 911 (Boehringer Mannheim, Roche) by
n enzymatic colorimetric method, following the manufac-
urer’s instructions. LDL cholesterol values were calculated
sing the Friedewald formula.
.3. DNA analysis
Amplified fragments from genomic DNA comprising
ll exons of the LDLR gene, were analysed for muta-
ions by highly sensitive denaturing high pressure liquid
hromatography (DHPLC) (Transgenomics, USA) and auto-
ated sequencing. Large rearrangements in the LDLR were
dentified by multiplex ligation-dependent probe amplifica-
ion (MLPA) with the kit for the LDLR gene (SALSA P062B
it) from MRC-Holland (Amsterdam, The Netherlands), fol-
owing the manufacturer’s instructions. MLPA amplification
roducts were analysed with the GeneScan Analysis Soft-
are Version 3.1.2 and peak heights were measured with
enotyper Software Version 2.5 (Applied Biosystems) and
xported to excell sheets for further processing. The peak
the Portuguese FH study. (A) Portuguese network of clinicians currently
ents registered in the Portuguese FH study, by district.
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eights were normalised and then divided by average nor-
alized peaks from four normal control subjects. The results
re given as relative allele copy number as compared to nor-
al controls, so a ratio of ∼1 is obtained if both alleles are
resent, a ratio of ∼0.5 if an allele is absent and ∼1.5 if an
llele is duplicated.
APOB gene was analysed by amplification and sequencing
f a fragment of exon 26 containing the four most common
POB mutations and a fragment of exon 29 as described
efore [5].
All 12 exons of PCSK9 gene were amplified and
equenced as described before [6]
.4. LDLR and APOB gene haplotyping
LDLR haplotypes were analysed by PCR amplification
nd sequencing of fragments containing known common
ariants in this gene namely, 81T > C (SfaNI), 1060+10G > C
SmaI), 1171G > A (StuI), 1413G > A (BsmAI), 1617C > T
BstNI), 1773 C > T (HincII), 1959 T > C (AvaII), 2232G > A
MspI), 2389 +46, 2547 −80, 2547 −42 and 2583 +52, cor-
esponding to exon 2, intron 7, exons 8, 9, 11–13, 15, intron
6, 17 and 3′UTR region.
APOB haplotypes of patients with the APOB3500 mutation
ere determined by PCR amplification and restriction analy-
is and/or sequencing of four polymorphic sites in the APOB
ene, as described previously [7,8]
.5. Long-range PCR
For PCR amplification of large fragments of the LDLR
ene, Expand Long Template PCR System was used accord-
ng to manufacturer’s instructions (Roche Applied Science).
he reactions were carried out in a Biometra T3000 thermo-
ycler (Germany). The fragments obtained were analysed by
irect sequencing.
.6. Analysis of human single tandem repeats
Single tandem repeats (STR) analysis was performed as
test for paternity using the AmpFlSTR® Profiler PlusTM
ollowing manufacturer’s instructions (Applied Biosystems,
SA). The products obtained were analysed with the Gen-
mapper Software Version 3.7 (Applied Biosystems)
All sequencing reactions, MLPA reactions and STR anal-
sis described here were analysed in a 3100 Genetic Analyser
ith 16 capillaries (Applied Biosystems, USA) using POP6
olymer according to the manufacturer’s instructions. PCR
onditions and primers are available on request.
.7. Statistical analysisAll data were analysed with SPSS software (version
3.0). To test for association between variables, the Pear-
on Chi square test and the Fisher exact test were used.
hen these could not be applied, non-parametric tests were
a
L
t
isis 196 (2008) 633–642 635
sed: Mann–Whitney (for two independent samples) and
ruskall–Wallis (for more than two independent samples).
or all tests used p < 0.05 was considered statistically signif-
cant.
. Results
.1. Clinical data analysis
The clinical and biochemical characteristics and relevant
ife habits of the 184 Portuguese FH patients are summarized
n Table 1.
.2. Molecular analysis
.2.1. LDLR
Fifty-three different mutations were found in 83 index
atients, 23 of which have not been described previously
Table 2a). These include 31 point mutation, 3 nonsense
utations, 6 splice site mutations, 11 small deletions and
nsertions and 2 large deletions. Additionally, 2 alterations,
missense and 2 potential splicing alterations, were found
n 8 index patients (Table 2b) where in all but one, other
utations have not been found in APOB, LDLR or PCSK9.
he pathogenicity of these alterations is not clear, mainly due
o lack of co-segregation of the alteration with hypercholes-
erolaemia in the family. One of these alterations, G248D, has
een described before as a mutation causing disease (online
H database: www.ucl.ac.uk/fh) but it did not co-segregate
ith the hypercholesterolaemia in one of the three different
amilies where this alteration was found. In fact in this family
his alteration was not present in two hypercholesterolaemic
elatives and it was found in two normolipidaemic relatives.
his suggests that this variant has no deleterious effect on
DL receptor function. Another alteration, 818 −2A/G, was
dentified in this family that co-segregates with the hyper-
holesterolaemia in this family (Fig. 2A) and was for this
eason considered the mutation causing disease.
Four patients were found to carry two defective LDLR
lleles, even though three of these patients did not present a
ypical “homozygous” phenotype (Table 3): one homozygous
or V408L, one homozygous for A410T and one compound
eterozygous for A410T and a potential splicing mutation
13+6T/C. The compound heterozygous patient inherited the
13+6T/C mutation from her father but the A410T mutation
as appeared de novo in her maternal allele and she trans-
itted it to her two sons. This result was confirmed by the
nalysis of human STRs (data not shown) that proved that
he mother was indeed the biological mother.
Patients in whom no mutation in the LDLR or APOB
enes could be identified by dHPLC and/or sequencing were
nalysed by MLPA to search for large rearrangements in the
DLR gene. Two large deletions were found by MLPA in
hree unrelated patients with a severe FH phenotype; one
ndex patient was found to carry an allele with deletion of
636 M. Bourbon et al. / Atherosclerosis 196 (2008) 633–642
Table 1
Patient distribution in the paediatric and adult groups. Clinical and biochemical characteristics, smoking and alcohol consumption habits percentages
Paediatric (under 18) n Adults n
Age (years) 9.98 ± 3.89 51 46.63 ± 13.82 130
BMI (kg/m2) 19.92 ± 3.45 51 26.11 ± 4.95 119
Female (%) 54.9 28 60.9 81
Male (%) 45.1 23 39.1 52
Total cholesterol (mg/dl) 297.95 ± 7.84a 46 361.72 ± 84.55 89
248 ± 53.19b 46 279 ± 81.5 115
LDL cholesterol (mg/dl) 221.53 ± 66.69a 40 276.01 ± 85.82 75
168 ± 48.74b 46 209 ± 191.36 115
HDL cholesterol (mg/dl) 56.05 ± 17.90a 40 52.47 ± 15.08 79
58 ± 15.56b 46 57 ± 15.35 115
Triglycerides (mg/dl) 110.29 ± 76.69a 42 162.61 ± 114.59 81
111 ± 67.54b 46 153 ± 110.14 115
ApoB (mg/dl) 109.23 ± 55.58b 46 147.32 ± 67.22 115
ApoAI (mg/dl) 136.08 ± 34.95b 46 138.74 ± 35.11 115
Lp(a) (mg/dl) 73.45 ± 80.01b 45 65.41 ± 65.03 111
Alcohol consumption (%) 2.0 1 36.8 46
Smokers (%) 2.0 1 15.0 19
Hypertension (%) 2.0 1 28.7 37
Diabetes (%) 0.0 0 1.6 2
Thyroid (%) 0.0 0 4.7 6
Tendon xanthomas (%) 0.0 0 8.5 11
CHD (%)c 0.0 0 25.4 33
On medication (%)d 34 17 88.8 111
Exercise (%) 56.0 28 39.5 49
a Values before medication. Not available for all individuals.
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3b Values at present time, most under medication; only obtained for 161/18
c CHD is considered angina, coronary artery bypass graft (CABG) and m
d Medication is considered statins, fibrates, eztimibe and resins in the pae
xons 8–12 and, the other two patients, carried a deletion of
he 5′-end of the LDLR gene, comprising the promoter, exons
and 2, plus the deletion of exons 8–12, as showed in Fig. 3
or one of the patients. These mutations were also found in
elatives of these index patients. In individuals that showed
alf the normal copy number of exons 8–12, the deletion of
hese five exons was confirmed by long-range PCR (Fig. 3C).
he pattern of inheritance in the family indicated that both
eletions occurred on the same allele. The haplotype analysis
f these three patients revealed that they share the same hap-
otype for the mutant allele: C (1060 +1), G (2232), C (2389
46), G (2547 −80), G (2547 −42).
The most common mutation, A410T, represents 13% of
ll genetically identified FH cases in this study and only
wo different haplotypes have been found: C (81, SfaNI),
(1060 +10, SmaI), G (1171, StuI), G (1413, BsmAI), C
1617, BstNI), T (1773 HincII), C (1959, AvaII), G (MspI)
nd C (81, SfaNI), G (1060 +10, SmaI), G (1171, StuI), A
1413, BsmAI), C (1617, BstNI), C(1773 HincII), T (1959,
vaII), G (MspI).
.2.2. APOB
Three unrelated patients with clinical diagnosis of FH
ere found to be heterozygous for the R3500Q mutation
n the APOB gene. The mutation was also found in three
ypercholesterolaemic relatives of these patients. The geno-
ypes for four APOB polymorphic sites were determined in
hese individuals. The R3500Q allele was associated with the
1
tpatients.
l infarction.
roup.
aplotype PvuII−/XbaI−/MspI+/EcoRI− in the three fam-
lies although we did not have relatives of the third family
nd so this haplotype is only estimated. These are the first
POB3500 patients to be described in the Portuguese popu-
ation and carry the same Caucasian haplotype as described
efore [7]
.2.3. PCSK9
Two unrelated patients and one relative were found to be
eterozygous for a novel mutation in PCSK9, predicted to
ause a single amino acid substitution, D374H. These patients
resented a very severe phenotype with extremely high total
holesterol levels, mean value of 505.40 ± 86.82 mg/dl ver-
us other FH patients with mean value of 353.93 ± 83.0 mg/dl
LDLR) and 279.54 ± 52.97 mg/dl (APOB), and several rel-
tives with premature CHD (Fig. 4 in supplement). Total
holesterol values in PCSK9 patients were significantly dif-
erent from those in LDLR and APOB patients (p = 0.034;
= 0.022). This mutation has not been reported before, but a
ifferent nucleotide substitution in the same codon has been
escribed in four English patients (D374Y) who also had a
ery severe phenotype [9].
.3. Cascade screeningScreening of 206 relatives in families of 88 index patients,
9 children (under 18) and 69 adults, lead to the identifica-
ion of 116 additional genetically diagnosed FH patients, 27
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Table 2a
Mutations found in the LDLR gene
Nucleotide change Predicted effect No of index patients No of relatives
c.-21A > C M-21L in signal peptide 1 0
[Pr EX2del+EX8 12del] Large deletion of 7 exons 1 8
c.226G>T G55W in ligand binding domain 1 3
c.241C > T R60C in ligand binding domain 1 0
c.265T > C C68R in ligand binding domain 1 2
c.292G>C G77R in ligand binding domain 1 0
c.313+1G > A Splicing error 1 0
c.313+6T>C Splicing error 1 1
c.326G > T C88F in ligand binding domain 1 3
c.369 393del25 S102fsX176 1 1
c.530C > T S156L in ligand binding domain 3 7
c.551G > A C163Y in ligand binding domain 1 3
c.619 639del21 In frame. G186 S192del 1 2
c.631C>G H190D in ligand binding domain 1 0
c.661G > T D200Y in ligand binding domain 1 1
c.662A > G D200G in ligand binding domain 1 1
c.682G > A D203N in ligand binding domain 7 14
c.670G > A E207K in ligand binding domain 1 0
c.818 −2A>G Splicing error 2 4
c.862G > A E267K in ligand binding domain 1 0
c.1016 1017insG L318fsX336 1 3
c.1027G > A G322S in EGF precursor homology domain 1 1
c.1031C > T Stop codon. Q324X 1 3
c.1048C > T Stop codon. R329X 1 0
c.1060+1G > A Splicing error 2 0
c.1085delA D341fsX348 1 1
c.1178delA K372fsX392 1 0
EX8 12del Large deletion of 5 exons 1 4
c.1216C > T R385W in EGF precursor homology domain 4 9
c.1222G > A E387K in EGF precursos homology domain 1 0
c.1285G>C V408L in EGF precursor homology domain 1 0
c.1291G > A A410T in EGF precursor homology domain 11 14
c.1432G > A G457R in EGF precursor homology domain 2 4
c.1455C>G H464Q in EGF precursos homology domain 1 1
c.1468T>C W469R in EGF precursor homology domain 1 3
c.1633G>T G524W in EGF precursor homology domain 1 1
c.1659 1661delCTCinsATACTTTCA Stop codon. Y532X 1 1
c.1690A > C N543H in EGF precursor homology domain 1 0
c.1775G > A G571E in EGF precursor homology domain 3 4
c.1816G > T A585S in EGF precursor homology domain 3 0
c.1840T>A F593I in EGF precursor homology domain 1 1
c.1845+1delG Splicing error 1 0
c.1886delT F608fsX642 1 0
c.1935 1936delA N624fsX646 1 1
c.1942T>C S627P in EGF precursor homology domain 1 0
c.1999T > C C646R in EGF precursor homology domain 1 0
c.2053C > T P664S in EGF precursor homology domain 1 0
c.2056C > T Stop codon. Q665X 1 3
c.2077 2078delAA K672fsX694 1 1
c.2389G > A V776M in membrane spanning domain 1 5
c.2399 2403delTCTTCinsGGGT V779fsX910 1 0
c.2417 2418insG V785fsX795 1 0
c.2547+1G>A Splicing error 2 2
Novel mutations are in bold.
638 M. Bourbon et al. / Atherosclerosis 196 (2008) 633–642
Table 2b
Putative mutations causing disease found in the LDLR gene
Nucleotide change Predicted effect No index patients No relatives
c.806G > A G248D in ligand binding domain 4 6
c.1061 −8T > C Splicing error? 1 7
c
c domain
N
c
a
3
P
P
p
o
t
t
F
a
s
i
b
p
n
g
t
i.1359 −5C>G Splicing error?
.2575G>A V838M in internalisation signal
ovel alterations are in bold.
hildren and 89 adults, making a total of 46 children and 158
dults genetically identified as having FH.
.4. Patients with no mutations in LDLR, APOB and
CSK9 genes
No alteration could be found in the LDLR, APOB gene or
CSK9 gene of 88 patients, 16 of whom presented a severe
r
p
l
m
ig. 2. Pedigrees of families where a putative alteration in the LDLR was found bu
rrow indicates the index patient. Age in years and total cholesterol values in mg/dL
haded symbols represent heterozygous individuals for the alteration found. Open
ndividuals who were not screened. (A) Pedigree of the familiy of the index patient
lack) G248D is found in two normolipidaemic individuals and on none of the hy
atient with the 1061 −8 T/C (half shaded black) alteration. The hypercholesterola
ormolipidaemic as far as we know. (C) Pedigree of the family of the index patient
randmother (I:2) does not have the alteration and the grandfather is normolipidaem
he 1359 −5 C/G (half shaded black) alteration. The hypercholesterolaemic son (II:
n this figure legend, the reader is referred to the web version of the article.)2 3
1 1
henotype with extremely high total cholesterol (mean value
f 321.6 ± 66.0 mg/dl, mean age 48.6 ± 12.9) and prema-
ure heart disease as well as strong family history and will
herefore be candidates for mutations in other genes. The
emaining 72 patients, 28 children and 44 adults, did not
resent with premature CHD but had severe hypercholestero-
aemia (children mean total cholesterol value of 255.9 ± 29.9,
ean age 10.0 ± 4; adults, mean total cholesterol value of
t does not co-segregate with the hypercholesterolaemia in the family. The
(*correspond to values on treatment) are shown below each symbol. Half
symbols represent individuals where the alteration was not found (Nor) or
with the G248D (half shaded red) and 818 −2 A/G mutation (half shaded
percholesterolaemic individuals. (B) Pedigree of the familiy of the index
emic grandmother (I:2) does not have the alteration and the grandfather is
with the V838M (half shaded black) alteration. The hypercholesterolaemic
ic as far as we know. (D) Pedigree of the family of the index patient with
3) does not have the alteration. (For interpretation of the references to color
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Table 3
Clinical and molecular characteristics of Portuguese FH homozygous
Subject Mutations Age Sex BMI Lipid values TC LDL-c HDL-c TG Apo A–I Apo B Clinical data
1 [V408L] + [V408L] 55 F 23.2 w/o treat – – – – – – Stenosis
On treat 299 232 47 99 100.0 139.0
2 [A410T] + [313+6C > T] 36 F 30.4 w/o treat 490 435 42 64 117.0 245.7 –
On treat 377 298 51 142 132 187.3
3 [A410T] + [A410T] 25 F 18.5 w/o treat 596 512 65 96 – – –
On treat 370 299 54 84 119.0 156.9
4 H190D + K372fsX392 + A585Sa 29 M 25.1 w/o treat 561 515 – – – – MI, 23 years CABG,
CA, 24 yearsOn treat 346 298 29 96 86.0 189.3
Treat, treatment; TC, total cholesterol; TG, triglycerides; all lipids values are given in mg/dl. MI, myocardial infarction; CABG, coronary artery bypass graft;
CA, coronary angioplasty.
a Parents were not available for testing so it could not be determined which mutations were in the same allele.
Fig. 3. Proband pedigree, mutation detection by MLPA and confirmation by PCR amplification. (A) Proband pedigree. The arrow indicates the index patient.
Age in years and total cholesterol values in mg/dL (*correspond to values on treatment) are shown below each symbol. Half shaded black symbols represent
heterozygous individuals for the deletion of promoter + exons 1–2 and 8–12. Open symbols represent normolipidaemic individuals (Nor) where the mutation
was not found or individuals who were not screened. (B) After normalization of all the peak heights relative to control samples, the normal height of each peak,
corresponding to the amplification product of all the exons of the LDLR gene and several control sequences, is ∼1. If the gene has a large rearrangement, such
as the deletions found in this patient, the relative height of the peak drops to ∼0.5. (C) Long PCR amplification of a fragment comprising exon 7–exon 13.
The fragment obtained for index patient and affected relatives with the deletion of exons 8–12 was ∼2.1 kb and the normal allele was not amplified (9.73 kb).
M, 1 kb ladder; lane 1, index patient (II:3, 20042); lane 2, relative III:5, lane 3, relative III:4; lane 4, relative III:6; lane 5, relative III:7; lane 6, relative III:8.
Abbreviations: †, deceased; MI, myocardial infarction; TX, tendon xanthomas.
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43.6 ± 64.4, mean age 47.2 ± 11.2) and a family history of
ncreased cholesterol values, consistent with a genetic disor-
er of lipid metabolism.
.5. Statistical analysis
Only patients with an LDLR mutation were considered
or this analysis.
.5.1. Comparison by mutation, age, sex and CHD
ccurrence
The statistical analysis revealed that patients with muta-
ions that lead to mRNA instability (stop codons, frameshift
utations, large deletions and splicing mutations) have
igher total cholesterol values (p = 0.025) than patients with
issense mutations, but there was no significant effect of
utation type or (age-adjusted) plasma cholesterol levels on
ncidence of CHD.
When the adult population was compared between sexes, it
as observed that a higher percentage of males were smokers
p = 0.006) and a higher percentage of males presented with
HD (p = 0.042). Female FH patients with CHD were older
p = 0.004) and had higher Lp(a) values (p = 0.039) than FH
emales without CHD and the same was seen in the male
roup (p = 0.022; p = 0.048).
There were no significant differences in biochemical char-
cteristics between sexes in the paediatric group.
.5.2. Comparison between countries
Age, BMI, total cholesterol values, LDL cholesterol val-
es, % of patients with premature CHD and % of patients
ith tendon xanthomas were compared between Portugal
nd Spain and between Portugal and the UK. Spanish val-
es were obtained from the literature [10] and UK data was
indly provided by Dr R. Naoumova, Hammersmith Hos-
ital Lipid Clinic. There were no significant biochemical
ifferences between FH patients from Portugal and Spain
xcept for total cholesterol values which are higher in Spanish
omen than in Portuguese women. Perhaps more surprising,
H patients in the UK do not exhibit higher values of total
r LDL cholesterol than Portuguese patients and do not have
higher incidence of CHD than Portuguese or Spanish FH
atients. This is despite a higher occurrence of tendon xan-
homas in the UK, present in only 8.5% of Portuguese FH
atients, 22.5% of Spanish FH patients and 78.8% of English
H patients, although the mean age of the UK patients was
ignificantly greater than the Portuguese (56.8 ± 17.1 versus
8.7 ± 14.2).
. DiscussionA network of lipid clinics was established for the Por-
uguese FH study and we regularly receive samples for this
tudy. A genetic defect was identified in 88 patients with FH,
f whom 79 were heterozygous for a mutation in the LDLR,
s
a
t
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wo were true homozygous and two were compound het-
rozygous for two different alleles, three were heterozygous
or the APOB3500 mutation and two for a novel mutation in
he PCSK9. These patients represent approximately 50% of
he clinical FH patients referred to our study. Twenty-three
utations in the LDLR gene and the mutation in the PCSK9
ene have not been reported before, being until date, exclu-
ive to the Portuguese population as far as we know. Family
tudies lead to the additional identification of 116 affected
elatives, increasing the number of FH patients identified
enetically to 204.
The majority of the described alterations, specially the
oint mutations, fulfilled all the accepted criteria for a func-
ional mutation [11] except the functional studies that are
till being performed for the few exceptions. Additionally,
our alterations were found in eight patients but were not
onsidered mutations causing disease, since they did not co-
egregate in the families with the hypercholesterolaemia or
ere alterations in non-coding regions close to the intron
xon junction that potentially affect splicing. These four
utative functional alterations are under investigation. Co-
egregation of the mutation with the hypercholesterolaemia
n the families studied was always a strong criteria that has
een followed by our group and a report has only been sent to
he assistant clinician when relatives were available to con-
rm this. Other mutations have been described as fulfilling
lmost all Cotton criteria and subsequently proven not to be
functional mutation [12] similarly to one of our index cases
Fig. 2A), so all attention has to be given to mutations that do
ot fulfil all these criteria and functional studies should be per-
ormed. Unfortunately only a few, for example A410T [13]
r 313 +1 [14] have been proved by independent functional
tudies to be the causal mutation.
The importance of always studying the whole gene was
lso supported by one of the cases presented (Fig. 2A) where
he first mutation found did not co-segregate with hyperc-
olesterolaemia in the family, but when the whole gene was
tudied a splice site mutation was found that co-segregated
ith the phenotype in the family. However, the first alteration
ound in this family (G248D) that was not considered to be
he mutation causing disease, was also found in other three
nrelated FH families without any other detectable defect in
he three genes studied. Thus it is possible that this muta-
ion could have a mild effect and functional studies are being
erformed.
Based on the estimated frequency of homozygous FH in
urope (about one in a million) [1], Portugal should have
bout 10 homozygous patients, but to our knowledge, none
ave been described. Four patients have been identified in our
tudy with two defective alleles of the LDLR but only one
resented with a typical homozygous phenotype. For one of
he compound heterozygous patients, there is an explanation,
ince it was observed that the mutation in the donor splice site
ppears to result in mis-splicing of only a small portion of
he mRNA from that allele (data to be reported elsewhere).
or the patient homozygous for V408L, the only explanation
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s that some modulation by environmental and genetic fac-
ors produces the less severe phenotype and for the patient
omozygous for the A410T perhaps CHD has not yet devel-
ped due the young age of this patient. In fact the only patient
ith a typical homozygous phenotype only developed CHD
t age 22 and smoked 20 cigars per day.
Several distinct mutations were found in our population, as
een in most European countries, but few alterations occurred
ore than once. All these more frequent mutations were
ound in apparently unrelated index patients but several hap-
otype analysis revealed evidence for a common ancestor.
he haplotype analysis of the 11 patients carrying the A410T,
he most frequent mutation accounting for 13% of all muta-
ions found, showed that this mutation could have occurred
wice since only two different haplotypes were found. Also
he majority of these patients come from the same region in
he south, which could imply that these patients must have
common ancestor. Since all patients with del exon 8–12
hare the same haplotype it could be possible that they share
common ancestor and that the promoter region plus exons
and 2 deletion occurred subsequently on the allele already
arrying the exon 8–12 deletion. The patients carrying the
203N probably have a common ancestor since the patients
r their parents come from the same village in the Algarve and
family connection was subsequently revealed between three
f these patients. The existence of a few common mutations
ould help the establishment of a rapid genetic diagnosis for
H in Portugal, but insufficient patients have yet been studied
o determine correctly the frequency of these most common
utations.
Interestingly only four mutations were found in common
ith the Spanish FH population, namely M-21L [15], S156L
16], D200G [17], and G322S [18] and this last one also with
he Brazilian population [19]. From the available literature it
eems that not enough FH patients have been studied in these
hree countries for results in the populations to be compared.
astillo and co-workers [20] described 13 Spanish patients
ith the APOB3500 mutation, 11 coming from a region just
orth of Portugal. Surprisingly our three patients are from a
entral region of Portugal and share the same haplotype.
In two unrelated patients a mutation was identified in the
CSK9 gene, as well as in one relative. All these patients pre-
ented a very severe phenotype with premature CHD, as other
atients with similar PCSK9 mutations [9]. The mutation
escribed, D374H has not been described before although,
nother nucleotide change has been described in the same
odon (D374Y) [21] that is accepted as a functional mutation
22,23].
It was not possible to identify a mutation in any of the three
enes analysed in about 50% of the clinical FH patients stud-
ed, although 16 presented a severe phenotype with very high
otal cholesterol values and premature CHD. Other genetic
auses for hypercholesterolaemia have to be sought and there-
ore these patients will be good candidates for other gene
efects yet to be known to be involved in FH. The most inter-
sting patients belong to the paediatric group since in these
u
w
t
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atients, hypercholesterolaemia due to environmental factors
an be more easily ruled out. The possibility that a mutation in
he studied genes could have been missed must be considered
ince no method is 100% effective.
To determine if the phenotype of Portuguese FH patients
esembles that of a group of FH patients from Spain, a neigh-
ouring country with shared ancestors and culture, first of
ll the lipid profile of these two general populations was
ompared. Surprisingly, this revealed that total mean choles-
erol in the Spanish population is significantly lower than
n the Portuguese, that is 4.9 mmol/l versus 5.5 mmol/l for
en and 5.0 mmol/l versus 5.5 mmol/l for women [24,25].
n contrast, the values for the Portuguese population are
ery similar to the ones found in the English population,
.5 mmol/l for male and 5.6 mmol/l for women [26] despite it
eing a north European country with a distinct geography and
ulture from Portugal. Thus it seemed less certain that Por-
uguese and Spanish FH patients would be similar. However,
hen the clinical characteristics of Portuguese and Spanish
H patients were compared there were no statistically signif-
cant differences in age, BMI, pre-treatment total cholesterol
except for women), LDLc and percentage of patients with
HD. The Portuguese FH patients were also compared to a
roup of English FH patients from the Hammersmith Hospi-
al Lipid Clinic and the only significant difference observed
as a higher percentage of patients with tendon xanthomas
n English FH patients. However the similarity of the clin-
cal characteristics of FH patients of these three countries
ith different backgrounds could be limited in this analysis
ecause the numbers of these three groups of patients are
ery different. Since there are no differences in mean lipid
evels in the FH population between these three countries,
wo alternative explanations could be advanced to explain
he fact that UK FH patients have such a high percentage
f tendon xanthomas; either tendon xanthomas are not being
ell diagnosed in Portugal or Portuguese FH patients are
ess susceptible to the development of tendon xanthomas for
ome environmental reason. The first explanation seems to be
ore plausible since a more recent publication [27] showed
hat 40% of Spanish FH patients had tendon xanthomatosis
hen tendon ultrasonography was used to analyse Achilles
endon xanthomas.
FH fulfils the World Health Organization criteria for
creening programs [28]. Since the introduction of statins
HMG-CoA reductase inhibitors), in the last decade, the
rognosis of FH patients has improved substantially and
herefore it is considered appropriate to do a systematic
creening for FH [29] and there are no negative ethical impli-
ations in the study of this disorder. Nevertheless FH is
everely under-diagnosed in Portugal, this being the first clin-
cal and molecular study of FH in this country. The number of
H patients studied is still very small but steps are now being
ndertaken to increase this number, namely a collaboration
ith the Portuguese Cardiology Society that will allow, in
he next 3 years, the complete study of 300 new families with
H. After the national publication of this study [3], our NHS
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as become aware of the importance of early identification
f this disorder as part of a programme for the prevention
f premature CHD and has given its scientific support to the
ortuguese FH Study.
The newly identified FH patients are now receiving coun-
elling and treatment based on the genetic diagnosis and it is
xpected that some of the younger patients may not develop
remature CHD due to the early identification of their disease
hrough this study. The present study also helped to establish
he appropriate therapeutic regime for each patient. None of
he patients ceased their medication because a mutation was
ot found in the LDL receptor gene, but several patients in
hom a mutation was found were treated subsequently with
more aggressive therapeutic regime.
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